IRIS
ROSSI, Marco
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.688
AS - Asia 981
EU - Europa 742
SA - Sud America 149
Continente sconosciuto - Info sul continente non disponibili 19
AF - Africa 13
OC - Oceania 6
Totale 3.598
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.629
SG - Singapore 505
IT - Italia 365
CN - Cina 291
BR - Brasile 121
SE - Svezia 100
DE - Germania 86
GB - Regno Unito 72
IN - India 52
CA - Canada 48
VN - Vietnam 40
FI - Finlandia 28
NL - Olanda 19
EU - Europa 18
FR - Francia 16
HK - Hong Kong 16
BD - Bangladesh 15
JP - Giappone 15
RO - Romania 13
ES - Italia 10
MX - Messico 9
AR - Argentina 8
RU - Federazione Russa 8
UA - Ucraina 8
EC - Ecuador 7
PK - Pakistan 7
TW - Taiwan 7
CZ - Repubblica Ceca 6
AU - Australia 5
CL - Cile 5
IR - Iran 5
TR - Turchia 5
ID - Indonesia 4
IQ - Iraq 4
CH - Svizzera 3
CO - Colombia 3
EG - Egitto 3
PL - Polonia 3
PY - Paraguay 3
SA - Arabia Saudita 3
UZ - Uzbekistan 3
ZA - Sudafrica 3
AT - Austria 2
DZ - Algeria 2
MY - Malesia 2
NP - Nepal 2
AE - Emirati Arabi Uniti 1
ET - Etiopia 1
GE - Georgia 1
GR - Grecia 1
GT - Guatemala 1
KE - Kenya 1
KR - Corea 1
LB - Libano 1
LT - Lituania 1
MA - Marocco 1
MN - Mongolia 1
NZ - Nuova Zelanda 1
PA - Panama 1
PT - Portogallo 1
SN - Senegal 1
TN - Tunisia 1
UY - Uruguay 1
VE - Venezuela 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 3.598
Salva come PNG Salva come JPEG
Città #
Singapore 243
Chandler 230
Dallas 159
Santa Clara 132
Hefei 126
Milan 110
Lawrence 106
Princeton 106
Munich 59
Wilmington 58
Ashburn 57
Chicago 53
London 48
Catanzaro 47
Des Moines 40
Beijing 35
Ottawa 28
Los Angeles 23
Ho Chi Minh City 22
Turku 22
New York 19
Brooklyn 16
Council Bluffs 16
Hong Kong 16
Guangzhou 13
Redwood City 13
Pune 12
São Paulo 12
Boardman 11
Shanghai 11
Redmond 10
Rome 10
San Francisco 10
The Dalles 10
Tokyo 10
Montreal 8
Charlotte 7
Hanoi 7
Naples 7
Columbus 6
Cosenza 6
Helsinki 6
Horia 6
Jiaxing 6
Leawood 6
Mountain View 6
San Jose 6
Timisoara 6
Ahmedabad 5
Atlanta 5
Augusta 5
Kulgam 5
Manchester 5
Olomouc 5
Reggio Calabria 5
San Nicola Manfredi 5
Berlin 4
Dhaka 4
Hanover 4
Mexico City 4
Norwalk 4
Paris 4
Phoenix 4
San Antonio 4
Settingiano 4
Stockholm 4
Taoyuan District 4
Utrecht 4
Zhengzhou 4
Andover 3
Ankara 3
Barcelona 3
Bari 3
Boston 3
Castrovillari 3
Cetraro 3
Chennai 3
Clifton 3
Delhi 3
Dongyang 3
Edmonton 3
Ferrara 3
Guayaquil 3
Karachi 3
Kumar 3
Masera 3
Mumbai 3
Nanjing 3
Rio de Janeiro 3
Rochester 3
Salvador 3
Santo Stefano di Rogliano 3
Shenzhen 3
Tashkent 3
Toronto 3
Warsaw 3
Wuxi 3
6th of October City 2
Adams Center 2
Alexandria 2
Totale 2.158
Salva come PNG Salva come JPEG
Nome #
A Comprehensive Safety Evaluation of Trabectedin and Drug-Drug Interactions of Trabectedin-Based Combinations 140
A Novel Bispecific T-Cell Engager (CD1a x CD3ε) BTCE Is Effective against Cortical-Derived T Cell Acute Lymphoblastic Leukemia (T-ALL) Cells 108
miR-22 suppresses DNA ligase III addiction in multiple myeloma 90
MiR-29b antagonizes the pro-inflammatory tumor-promoting activity of multiple myeloma-educated dendritic cells 66
Raman Spectroscopic Stratification of Multiple Myeloma Patients Based on Exosome Profiling 61
Therapeutic afucosylated monoclonal antibody and bispecific T-cell engagers for T-cell acute lymphoblastic leukemia 58
Use of hydroxychloroquine in hospitalised COVID-19 patients is associated with reduced mortality: Findings from the observational multicentre Italian CORIST study 57
LNA-Gapmer Antisense Oligonucleotides Targeting the Oncogenic Lncrna MALAT1 Trigger Anti-Multiple Myeloma Activity By Proteasome Blockade 57
Evidence of shared epitopic reactivity among independent B-cell clones in Chronic Lymphocytic Leukemia patients 54
A peroxisome proliferator-activated receptor gamma (PPARG) polymorphism is associated with zoledronic acid-related osteonecrosis of the jaw in multiple myeloma patients: analysis by DMET microarray profiling 52
MIR-21 SUPPRESSION IMPAIRS TH17 RELATED BONE DISEASE IN MULTIPLE MYELOMA 51
MYC-MIR-22 REGULATORY LOOP MODULATES LENALIDOMIDE ACTIVITY IN MULTIPLE MYELOMA CELLS 51
miR-21 antagonism abrogates Th17 tumor promoting functions in multiple myeloma 49
Autoimmune colitis and neutropenia in adjuvant anti-PD-1 therapy for malignant melanoma: efficacy of Vedolizumab, a case report 49
Trabectedin triggers direct and NK-mediated cytotoxicity in multiple myeloma. 48
ACTIVATION OF GPER SIGNALING AS A POTENTIAL THERAPEUTIC STRATEGY AGAINST WALDENSTROM MACROGLOBULINEMIA 47
A gene expression inflammatory signature specifically predicts multiple myeloma evolution and patients survival 46
Exploiting MYC-induced PARPness to target genomic instability in multiple myeloma 46
Anti-MALAT1 synthetic oligonucleotides target the proteasome and exert anti-multiple myeloma activity 45
Evidence of shared epitopic reactivity among independent B-cell clones in chronic lymphocytic leukemia patients 45
Direct Oral Anticoagulants: From Randomized Clinical Trials to Real-World Clinical Practice 45
Anti-tumor Activity and Epigenetic Impact of the Polyphenol Oleacein in Multiple Myeloma 44
MiR-34a Replacement As a Novel Therapeutic Approach for Multiple Myeloma: Preclinical In Vitro and In Vivo Evidence 43
Mir-221/222 are promising targets for innovative anticancer therapy 42
A unique three-dimensional SCID-polymeric scaffold (SCID-synth-hu) model for in vivo expansion of human primary multiple myeloma cells 42
Drugging the lncRNA MALAT1 via LNA gapmeR ASO inhibits gene expression of proteasome subunits and triggers anti-multiple myeloma activity. 41
Activation of the Non-Canonical Estrogen Receptor Gper As a Novel Therapeutic Strategy Against Waldenstrom Macroglobulinemia 41
Replacement of miR-155 Elicits Tumor Suppressive Activity and Antagonizes Bortezomib Resistance in Multiple Myeloma. 40
Alternative non-homologous end joining DNA repair as therapeutic target in multiple myeloma 39
Canonical and noncanonical Hedgehog pathway in the pathogenesis of multiple myeloma 38
CD7+ acute leukemia switching from a lymphoid to a myeloid phenotype 38
A comparative effectiveness study of lipegfilgrastim in multiple myeloma patients after high dose melphalan and autologous stem cell transplant 38
Immunogenomic identification and characterization of granulocytic myeloid-derived suppressor cells in multiple myeloma 38
Therapeutic vulnerability of multiple myeloma to MIR17PTi, a first-in-class inhibitor of pri-miR-17-92 38
Daunorubicina liposomiale in ematologia 37
The non-coding RNA landscape of plasma cell dyscrasias 37
Mycosis fungoides and gastric t-cell lymphoma: A case report 37
FlowCT for the analysis of large immunophenotypic datasets and biomarker discovery in cancer immunology 36
Therapeutic activation of G protein-coupled estrogen receptor 1 in Waldenström Macroglobulinemia 35
Complete remission induced by high dose erythropoietin and granulocyte colony stimulating factor in acute erythroleukemia (AML-M6 with maturation) 35
Challenging the Current Approaches to Multiple Myeloma-Related Bone Disease: From Bisphosphonates to Target Therapy 34
From target therapy to miRNA therapeutics of human multiple myeloma: theoretical and technological issues in the evolving scenario 34
Depression of lymphocyte activity during cutaneous leishmaniasis: a case report. 34
Intestinal toxicity during induction chemotherapy with cytarabine-based regimens in adult acute myeloid leukemia 33
Role of Nucleophosmin in embryionic development and tumorigenesis 33
Targeting miR-21 Inhibits In Vitro and In Vivo Multiple Myeloma Cell Growth 32
Contemporary antithrombotic strategies in patients with acute coronary syndromes managed without revascularization: Insights fromthe EYESHOT study 31
Mouse models of Multiple Myeloma: technologic platforms and perspectives 31
Drugging the lncRNA MALAT1 via LNA gapmeR ASO inhibits gene expression of proteasome subunits and triggers anti-multiple myeloma activity 31
miR-29s: a family of epi-miRNAs with therapeutic implications in hematologic malignancies 30
Molecular Targets for the Treatment of Multiple Myeloma 30
Peptide-loaded Langerhans cells, despite increased IL15 secretion and T-cell activation in vitro, elicit antitumor T-cell responses comparable to peptide-loaded monocyte-derived dendritic cells in vivo. 29
Enlarging the clinical spectrum of chorea-acanthocytosis 28
Therapeutic vulnerability of multiple myeloma to MIR17PTi, a first-in-class inhibitor of pri-miR-17-92 27
Immunotherapy with Monoclonal Antibodies for Acute Myeloid Leukemia: A Work in Progress 26
Immunologic microenvironment and personalized treatment in multiple myeloma 26
Quality of life outcomes in multiple myeloma patients: a summary of recent clinical trials 26
MicroRNAs in multiple myeloma and related bone disease 26
Role of gemcitabine-based combination therapy in the management of advanced pancreatic cancer: A meta-analysis of randomised trials 25
MiR-29b Exerts Anti-Multiple Myeloma Activity by Targeting Key Oncogenic Pathways and Modulating DNA Methylation Profile 25
miR-22 suppresses DNA ligase III addiction in multiple myeloma. 25
miR-29b sensitizes multiple myeloma cells to bortezomib-induced apoptosis through the activation of a feedback loop with the transcription factor Sp1 24
Synthetic miR-34a Mimics as a Novel Therapeutic Agent for Multiple Myeloma: In Vitro and In Vivo Evidence 24
Dendritic cells have the option to express IDO-mediated suppression or not 24
Translational Studies on the Bone Marrow Microenvironment in Multiple Myeloma: Experimental Models and Emerging Therapeutical Strategies 24
In vitro and in vivo activity of a novel locked nucleic acid (LNA)-inhibitor-miR-221 against multiple myeloma cells 23
In vitro and in vivo activity of a novel locked nucleic acid (LNA)-inhibitor-miR-221 against multiple myeloma cells 23
In vivo anti-myeloma activity and modulation of gene expression profile induced by valproic acid, a histone deacetylase inhibitor 23
Promises and Challenges of MicroRNA-based Treatment of Multiple Myeloma 23
Enumeration of IL-10-positive B cells from peripheral blood of Chronic Lymphocytic Leukemia patients 23
Tumor Suppressor MiR-29b Targets HDAC4 and Modulates Vorinostat Activity In Multiple Myeloma Cells 23
Emerging Role of MicroRNAs in the Pathophysiology of Immune System 23
Human Dendritic Cells: Potent Antigen-Presenting Cells at the Crossroads of Innate and adaptive Immunity 23
Common cardiovascular risk factors and in-hospital mortality in 3,894 patients with COVID-19: survival analysis and machine learning-based findings from the multicentre Italian CORIST Study 23
Replacement of miR-155 Elicits Tumor Suppressive Activity and Antagonizes Bortezomib Resistance in Multiple Myeloma 23
Frontline therapy CLL without 17p del/p53 aberrations: systematic review and Bayesian network meta-analysis 22
Primary large B-cell lymphoma involving the cerebellopontine angle mimic acoustic schwannoma: Role of MR Spectroscopy in differential diagnosis. A case report 20
MicroRNA and Multiple Myeloma: from Laboratory Findings to Translational Therapeutic Approaches 20
Network meta-analysis of randomized trials in multiple myeloma: efficacy and safety in relapsed/refractory patients. 20
Indoleamine 2,3-dioxygenase-expressing mature human monocyte-derived dendritic cells expand potent autologous regulatory T cells 20
Acute lymphoblastic leukemia in the context of a disorder resembling X-linked lymphoproliferative (XLP) syndrome 20
Selective targeting of IRF4 by synthetic microRNA-125b-5p mimics induces anti-multiple myeloma activity in vitro and in vivo 20
Selective targeting of IRF4 by sytnthetic microRNA-125b-5p mimics induces anti-multiple myeloma activity in vitro and in vivo 20
Non-Coding RNAs in multiple myeloma bone disease pathophysiology 20
Inhibition Of Mir-21 In HS-5 Bone Marrow Stromal Cells In The Presence Of Multiple Myeloma cells Restores RANKL/OPG Ratio: A Potential Therapeutic Approach For Myeloma-Related Bone Disease 19
Synthetic MiR-29b Mimics Potentiate Dendritic-Cell Based Immunotherapy Against Multiple Myeloma In Vitro and In Vivo 19
MiR-29b Counteracts Aberrant HDAC4 Expression and Enhances Vorinostat Activity in Multiple Myeloma 19
Inhibition of miR-21 restores RANKL/OPG ratio in multiple myeloma-derived bone marrow stromal cells and impairs the resorbing activity of mature osteoclasts 19
Multiple myeloma-related bone disease: state-of-art and future treatments 18
Non Homologous End Joining, a Marker Of Genomic Instability Is Elevated In Multiple Myeloma: A New Prognostic Factor 18
Gilteritinib: The Story of a Proceeding Success into Hard-to-Treat FLT3-Mutated AML Patients 17
New Approaches to Predict Outcome and Personalize Therapy in Multiple Myeloma: from microRNAs to Integrated Genomics 17
Genetics and molecular profiling of multiple myeloma: Novel tools for clinical management? 17
Targeting Aberrant Non-Homologous End Joining in Multiple Myeloma: Role of the Classical and Alternative Pathways in Genomic Instability 17
miR-29b targets HDAC4 and mediates activity of HDAC inhibitors in multiple myeloma cells 17
Hedgehog pathway in myeloma pathobiology and as potential therapeutic target 17
Multiple Myeloma Cells downregulatemiR-29b in dendritic cells to promote a tumor permissive inflammatory microenvironment and immune escape 17
Osteonecrosis of the Jaw Prevention and Management in Modern Oncology 17
miR-29b negatively regulates human osteoclastic cell differentiation and function: Implications for the treatment of multiple myeloma-related bone disease 16
Targeting miR-21 in bone marrow stromal cells restores RANKL/OPG ratio within multiple myeloma microenvironment 16
Totale 3.408
Salva come PNG Salva come JPEG
Categoria #
all - tutte 48.273
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 48.273
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021195 0 0 8 10 23 12 7 20 36 35 39 5
2021/2022319 9 4 4 72 36 17 10 58 25 30 48 6
2022/2023723 223 37 33 46 69 54 4 49 103 38 51 16
2023/2024325 74 44 23 18 26 87 8 7 2 9 13 14
2024/20251.375 190 93 67 69 96 167 30 40 142 69 144 268
2025/2026679 142 280 257 0 0 0 0 0 0 0 0 0
Totale 3.726